60 Degrees Pharmaceuticals (SXTP) announced it has determined the maximum size of the commercial market for ARAKODA for treatment of human babesiosis to be 380,000 patients/$245,000,000 in sales annually, with a cumulative TAM of 1.17 million patients/$1.1 billion through patent expiration in 2035. Human babesiosis is a serious and debilitating emerging tick-borne illness often found as a co-infection in patients with Lyme Disease. There is a substantial unmet medical need due to the lack of FDA-approved treatments and the frequent generation of resistance associated with repeated use of generic drugs to manage persistent disease.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SXTP:
- 60 Degrees Pharmaceuticals to submit tafenoquine MUMS designation request to FDA
- Closing Bell Movers: Merit Medical Systems gains after Q2 outlook
- 60 Degrees Pharmaceuticals to sell 2.04M shares of common stock for holders
- 60 Degrees introduces eight-count bottle format for ARAKODA
- 60 Degrees announces results from an insurance claims analysis on babesiosis